Wednesday

Pharma Webinars

Oct. 28th

1

11:00 am – 12:15 pm ET

The ability to claim larger health system productivity benefits from the introduction of chronic disease medicines looms in importance as these therapeutic segments become more crowded and competitive.

Category: Chronic Diseases

Katherine Vandebelt

Moderator:
Katherine Vandebelt 

Global Vice President, Clinical Innovation
Oracle Health Science

See here :

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

WHO IS SPEAKING

Douglas_Schlichting_Eli_Lilly_Pharma_Web_1

Douglas Schlichting, RN, PhD
Development Director
Immunology Product Development – baricitinib rheumatoid arthritis and COVID-19
Eli Lilly and Company

 

> More about the product

Olumiant_logo
David_Platt_Novartis_Pharma_Web_1

David Platt, MD
Vice President, Medical Unit Head
Cardiovascular, Renal & Metabolism Medical Unit  
Novartis Pharmaceuticals Corporation

 

> More about the product

Entresto_logo
Sandi See Tai

Dr. Sandi See Tai
VP, Medicine Team Lead for Amyloid, Rare Neuro & Cardiac
Pfizer Global Product Development
Pfizer Inc.

 

> More about the product

Vyndaqel_logo
Sailaja Bhaskar

Sailaja Bhaskar, BPharm, MS, PhD, MBA
Executive Director, Clinical Operations Planning
Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P.

 

> More about the product

Adhansia_logo
Eric_Pearlman_Eli_Lilly__BioTech_Web_1_Pharma_Web_1

Eric M Pearlman
Senior Medical Director-Neuroscience, US Medical Affairs

Eli Lilly and Company

 

> More about the product

Reyvow_logo

2

12:30 pm – 1:45 pm ET

What are the prospects – and limitations – behind the new approaches to cancer treatments from our increased knowledge of the underlying biology behind tumor growth and proliferation?

Category: Solid Tumor Cancers

Moderator:
Theodore F. Search, MD

Chief Executive Officer
Skipta

See here :

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

WHO IS SPEAKING

Mimi_Huizinga_Novartis_Pharma_Web_2_3

Mimi Huizinga, MD
Vice President and Head, US Oncology Medical
Novartis

 

> More about the product

Piqray_logo
Dr_Marc_Fellous_Bayer_Pharma_Web_2

Dr. Marc Fellous
Global Medical Affairs Head
Bayer

 

> More about the product

Vitrakvi_logo
Sam_Spigelman_Balversa_Pharma_Web_2

Sam Spigelman, MD
Senior Global Medical Affairs Leader
Janssen Research & Development, LLC

 

> More about the product

Balversa_logo
Sabine_Brookman-May_Erleada_Pharma_Web_2

Sabine Brookman-May, MD, PhD
Executive Medical Director, Late Development, Solid Tumor
Janssen Research & Development, LLC

 

> More about the product

Erleada_logo
Ted_Johnson_Pfizer_Pharma_Web2Ted_Johnson_Pfizer_Pharma_Web2

Ted W. Johnson, PhD
Research Fellow
Medicinal Chemistry, Pfizer Oncology
Pfizer Inc.

 

> More about the product

Lorbrena_logo
Dr_Jorge_Ortiz_Bayer_Pharma_Web_2

Dr. Jorge Ortiz
Global Medical Affairs Head

Bayer

 

> More about the product

Darolutamide_logo
Ute Simon_200p

Dr. Ute Simon
Head Global Medical Affairs
AAA ( a Novartis company)

 

> More about the product

Lutathera_logo

3

2:00 pm – 3:00 pm ET

Are there common links in advancing research on hematologic cancers and other rare diseases associated with uncontrolled vascular system inflammation, such as sickle cell anemia?

Category: Hematologic cancers and other rare diseases

Moderator:
Theodore F. Search, MD

Chief Executive Officer
Skipta

See here :

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

WHO IS SPEAKING

Dr_Ramon_Tiu_Astellas_Pharma_Web_3

Ramon V. Tiu, MD
Executive Medical Director, Astellas Pharma Global Development
Global Medical Leader, Gilteritinib Program
Astellas Pharma Inc.

 

> More about the product

Xospata_logo
Dr. Michael G. Kauffman

Dr. Michael G. Kauffman, MD, PhD
Chief Executive Officer
Co-Founder
Karyopharm Therapeutics Inc.

 

> More about the product

Xpovio_logo
Mimi_Huizinga_Novartis_Pharma_Web_2_3

Mimi Huizinga, MD
Vice President and Head, US Oncology Medical
Novartis

 

> More about the product

Adakveo_logo

4

3:00 pm – 4:00 pm ET

Will the coronavirus pandemic finally lead to an upswing in R&D to tackle neglected areas like antibiotic resistance, zoonotic transmission of pathogens and a more globally-coordinated approach to infectious diseases overall?

Category: Infectious diseases and reproductive health

Moderator:
MaryAnne Rizk, PhD

Senior Vice President, R&D Digital Strategy
IQVIA

See here :

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

WHO IS SPEAKING

Mark_Sullivan_MDGH_Pharma_Web_4

Mark Sullivan
Founder and Managing Director
Medicines Development for Global Health

 

> More about the product

1564116849MD_Logo
Amanda_Paschke_Merck_Pharma_Web_4

Amanda Paschke, MD, MSCE
Executive Director
Global Clinical Development
Merck & Co., Inc.

 

> More about the product

recarbrio-logo
Dennis_Hruby_Siga_Pharma_Web_4

Dennis E. Hruby, PhD
Chief Scientific Officer
SIGA Technologies, Inc.

 

> More about the product

1563901225SIGA-Full_Logo-3337x1675-500dpi
Daniel_Everitt_TB_Alliance_Pharma_Web_4

Daniel Everitt, MD
Vice President and Chief Medical Officer
TB Alliance

 

> More about the product

1595340100TBA_logo_2-color